Key Takeaways
- President Trump announced one-time $90 payments to over 20 million Medicare Part B enrollees to offset premium costs, utilizing the Medicare Improvement Fund for the first time.
- Iran's economy is in "freefall" with inflation nearing 90% and the rial hitting record lows as a U.S. naval blockade enters its seventh month.
- AbbVie (ABBV) and nine other major drugmakers joined a federal pilot program to transition 340B drug discounts to a back-end rebate model starting January 1, 2027.
- Russian jet-powered drones struck Kyiv’s Northern Bridge, severing critical transit lines and marking the third consecutive day of infrastructure attacks in the Ukrainian capital.
- President Trump reiterated a $5,000 "Trump Dividend" pledge for every U.S. citizen, contingent on a Republican victory in the upcoming November midterm elections.
Domestic Policy and Election Pledges
President Donald Trump announced on Saturday that his administration will immediately begin distributing $90 checks to more than 20 million seniors to assist with Medicare Part B premiums. The funding for these payments is sourced from the Medicare Improvement Fund, a $2 billion account established in 2008 that the President characterized as a previously "pointless slush fund." Most eligible seniors will receive the funds via direct deposit in early October, while others will receive physical checks by mail.
The announcement comes as the administration ramps up financial promises ahead of the November midterm elections. Trump also renewed his pledge to distribute a $5,000 "Trump Dividend" to every adult U.S. citizen if Republicans maintain control of both the House and Senate. Analysts estimate the dividend could cost approximately $1.2 trillion to $1.3 trillion, with the President suggesting tariff revenues would cover the expense.
Healthcare and Pharmaceutical Developments
AbbVie (ABBV) has officially joined a U.S. government pilot program designed to test a new rebate system for the 340B drug discount program. Under the new model, which is set to launch on January 1, 2027, pharmaceutical companies will shift from providing upfront discounts to issuing back-end rebates after verifying transaction eligibility. Other participants in the HRSA-led pilot include Pfizer (PFE), Merck (MRK), and AstraZeneca (AZN).
The pilot program aims to improve pricing transparency and prevent "double-dipping" where multiple discounts are applied to the same drug. However, the American Hospital Association has expressed deep concern, arguing the rebate model will impose "massive new administrative and financial burdens" on safety-net hospitals. AbbVie (ABBV) will initially test the model on three specific medicines: Imbruvica, Linzess, and Vraylar.
Global Conflict and Economic Strain
The seven-month-old conflict between the U.S. and Iran has pushed the Islamic Republic to the brink of economic collapse. Inflation in Iran is currently nearing 90%, and the national currency has plummeted to a record low of 2.5 million rials to the U.S. dollar. A continuous U.S. naval blockade in the Strait of Hormuz has effectively choked off Iran's crude exports, causing daily revenue losses estimated at $500 million.
In Ukraine, a Russian jet-powered strike drone hit Kyiv’s Northern Bridge on Saturday morning, damaging the roadway and severing power lines for the city's trolleybus network. This follows a series of strikes on the Southern Bridge, causing severe traffic congestion as municipal crews struggle to assess the structural integrity of the spans. Ukrainian officials noted the attacks appear part of an intensified campaign against critical infrastructure following Vladimir Putin’s September order to lift constraints on air operations.
Diplomatic Friction
Recent reports indicate that during the September summit between President Trump and Xi Jinping, Chinese officials made "unusual requests" to accommodate the 73-year-old leader's need for rest. These requests, which included a private lounge in the West Wing and the cancellation of a working lunch, reportedly cut roughly five hours from the summit's scheduled meeting time. The scheduling shifts have fueled renewed speculation regarding the Chinese President's physical health and stamina during high-stakes international diplomacy.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.